Proactive Investors
21 Oct 2026, 23:51 UTC · 1h ago
Recce Pharmaceuticals signs Arrotex deal for RECCE 327 in Australia and New Zealand
Impact · against what's priced in
Recce Pharmaceuticals secures a regional commercialization partner for R327G, reducing future regulatory and marketing expenses in Australia and New Zealand. However, the absence of upfront or milestone payments fails to alleviate immediate cash runway concerns for the Phase 3 program.
- RCE+0.20
No priced-in read yet
- In context
The deal with Arrotex removes the burden of regulatory filings and marketing costs in Australia and New Zealand, though it provides no immediate cash via upfront or milestone payments.
Read from the article alone
